Scientists from the Institute of Bioengineering of Catalonia (IBEC), in collaboration with the Hospital General Universitario Gregorio Marañón in Spain and two other groups in the USA, have made a big leap in heart regeneration advances by achieving heart grafts from human pluripotent stem cells for the first time in less than one month.
The collaborators, working in Spain and the USA, describe in the journalBiomaterials how they decellularized – removed the cells from – human hearts, all of which had been determined not suitable for transplantation by the Spanish National Transplant Organization. They left the extracellular matrix, the structure that provides cells with structural and biochemical support, intact.They then used genome-editing techniques on human pluripotent stem cells (hPSCs) – undifferentiated cells from which other cell types develop – to efficiently produce cardiomyocytes, or heart cells, which they then used to repopulate the extracellular matrices of the decellularized human ventricles. Pluripotent stem cells are crucial for this process, as the body is not able to generate new cardiomyocytes after heart attack or other damage.
The cells within decellularized human heart matrices showed a higher degree of physiological and molecular cardiac differentiation compared to those cultured on regular tissue culture plates, which has been the usual method up to now. It took just 24 days for these human cardiac grafts to exhibit the correct electrophysiological responses needed in cardiac function; in other words, similarly beating as a heart does.
This type of de- and recellularization of organs represents a promising strategy for the development of biofunctional organs for drug screening and personalized medicine. “Decellularization of a whole heart can lead to hundreds of acellular slices ready to use as scaffolds for the approach described here,” says Nuria Montserrat from IBEC, one of the three leading authors on the paper. “We anticipate that our fast procedure can be immediately applied in laboratories for cardiac engineering and disease modeling applied to humans.”
The work, which involved researchers from IBEC and the Hospital General Universitario Gregorio Marañón in Spain, as well as the University of Minnesota, the Texas Heart Institute, and the Salk Institute for Biological Studies in the USA, was supported in part by a European Research Council grant. It opens the door to advances towards achieving bio-artificial hearts populated by patients’ own stem cells.
To read the full article click here
BSc (Hons) Microbiology
Biovault Family CEO, Kate Sneddon, joined Biovault in July 2009 and became Chief Executive Officer in 2016. As health industry professional her experience includes working as a microbiologist and leader at GSK for over 10 years. Her expertise in cord blood banking has been recognised in her awards, features in Parliamentary Review and Parents Guide to Cord Blood, as well as contributions to research with UCL and others.